{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:07:15Z","timestamp":1790230035038,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Managing type\u20102 diabetes (T2D) in chronic kidney disease (CKD) patients requires consideration of kidney function, and many drugs have not been investigated thoroughly. Clinical studies have demonstrated Glargine U300 (Gla\u2010300) supports achievement of adequate glycemic control at low hypoglycemia risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Method<\/jats:title>\n                    <jats:p>This cross\u2010sectional study analysed routine data of 21\u2009359 T2D patients with CKD (1786 using Gla\u2010300; 19\u2009568 without any insulin) from the prospective Diabetes\u2010Patienten\u2010Verlaufsdokumentation (DPV) registry to evaluate patient characteristics and safety of Gla\u2010300 use across different CKD stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients on Gla\u2010300 had T2D onset at an earlier age (median age 55.1 vs. 62.3\u2009years), longer diabetes duration (17.3 vs. 11.3\u2009years), higher body weight (91.3 vs. 83.9\u2009kg) and HbA1c levels (7.3% vs. 6.7%) than non\u2010insulin patients (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Gla\u2010300 usage increased from CKD stage 1\u20134 (median dose 44 vs. 55\u2009units) with higher baseline HbA1c levels (7.2% vs. 7.4%). Although severe hypoglycemia rates were low, a slight increase (0.01%\/PY vs. 0.04%\/PY) was observed with decreasing estimated glomerular filtration rate levels. Compared to others, stage 5 CKD patients had a distinct profile with lower HbA1c levels (6.9%), body weight (90\u2009kg) and higher Gla\u2010300 usage (50\u2009units). Metformin, SGLT\u20102 inhibitors and GLP\u20101 RA were common concomitant drugs with diminished usage in advanced CKD stages, while Gla\u2010300 was common at all stages.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite variations in patient profiles, Gla\u2010300 is widely used across all CKD stages, particularly in advanced stages with a low rate of severe hypoglycemia, suggesting its safe administration in CKD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16245","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:19:36Z","timestamp":1740007176000},"page":"2485-2494","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of patient characteristics and safety of insulin glargine\n                    <scp>U300<\/scp>\n                    use in 21\u2009359 patients with type\u20102 diabetes and chronic kidney disease:\n                    <scp>DPV<\/scp>\n                    registry study"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0915-427X","authenticated-orcid":false,"given":"Anjaly","family":"Vijayan","sequence":"first","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine  Cloppenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-6459","authenticated-orcid":false,"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, ZIBMT University of Ulm  Ulm Germany"},{"name":"German Center for Diabetes Research (DZD)  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Forestier","sequence":"additional","affiliation":[{"name":"Diabetes Center Bad Aibling  Bad Aibling Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hess","sequence":"additional","affiliation":[{"name":"Diabetology Private Practice  Worms Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Rottmann","sequence":"additional","affiliation":[{"name":"Hellmig Hospital Kamen  Kamen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Wosch","sequence":"additional","affiliation":[{"name":"Specialized Diabetes Practice, Wosch  Hanau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center \u2013 University of Freiburg, Faculty of Medicine University of Freiburg  Freiburg im Breisgau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, ZIBMT University of Ulm  Ulm Germany"},{"name":"German Center for Diabetes Research (DZD)  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine  Cloppenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DPV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.296"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17346.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.861"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14043"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2904"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0529"},{"issue":"5","key":"e_1_2_12_11_1","article-title":"Sodium\u2010glucose co\u2010transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale P","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021020167"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000364909"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_12_17_1","first-page":"4","article-title":"Efficacy and safety of insulin glargine in type 2 diabetic patients with renal failure. Journal of","volume":"3","author":"Niafar M","year":"2012","journal-title":"Diabetes Metab"},{"key":"e_1_2_12_18_1","unstructured":"Ulm University.Diabetes\u2010Patienten\u2010Verlaufsdokumentation (DPV). Accessed October 23 2023.http:\/\/buster.zibmt.uni-ulm.de\/dpv\/index.php\/en\/"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.09.006"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0391-8"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S005"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02687-w"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01031-z"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2016(01)08"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa017"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86181"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.01025.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018813501188"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.01.028"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17346.x"}],"updated-by":[{"DOI":"10.1111\/dom.71370","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000}}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:54:59Z","timestamp":1761864899000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/dom.16245"],"URL":"https:\/\/doi.org\/10.1111\/dom.16245","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16245\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v4\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16245\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}